Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice.

ABSTRACT:

Introduction

Avacopan, a complement 5a receptor (C5aR) antagonist, is a therapeutic option for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and is used as a steroid-sparing agent. The efficacy and safety of avacopan were established in the pivotal phase III ADVOCATE trial. However, there remains a paucity of real-world evidence to confirm these findings across diverse clinical settings and populations.

Methods

We conducted a systematic review of 16 real-world studies evaluating the clinical outcomes of avacopan in patients with AAV. Using a meta-analytic approach, we compared efficacy and safety outcomes reported in these studies with those of the main trial. Key end points included clinical remission and incidence of adverse events.<

SUBMITTER: Berke I 

PROVIDER: S-EPMC12917383 | biostudies-literature | 2026 Apr

REPOSITORIES: biostudies-literature